Research map: Clinical Evaluation of Bysanti: A New Atypical Antipsychotic for Schizophrenia and Bipolar I Disorder

Back to the article

Papers in this map

  1. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia · Jeffrey Alan Lieberman · 2005 · 5920 citations · Cited by this paper
  2. Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis · 2026 · Related
  3. Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative · Kathleen Ries Merikangas · 2011 · 2672 citations · Cited by this paper
  4. The Need for Better Stewardship of Medication Use in Older Adults · 2026 · Related
  5. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis · Stefan Leucht · 2013 · 2572 citations · Cited by this paper
  6. Description of Treatment Strategies and Patient Outcomes for Hospitalized Patients With Lyme Carditis · 2026 · Related
  7. Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication · Kathleen Ries Merikangas · 2007 · 2431 citations · Cited by this paper
  8. Four-Year Evaluation of a Pharmacists-Providers Collaborative Iron Deficiency Clinic in Heart Failure Care · 2026 · Related
  9. Canadian Network for Mood and Anxiety Treatments ( CANMAT ) and International Society for Bipolar Disorders ( ISBD ) 2018 guidelines for the management of patients with bipolar disorder · Lakshmi N. Yatham · 2018 · 1855 citations · Cited by this paper
  10. Comment on “Safety and Efficacy of the Prescribing Practices of Ketamine for Pain and Agitation in the Medical Intensive Care Unit” · 2026 · Related
  11. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016 · Fiona Charlson · 2018 · 1704 citations · Cited by this paper
  12. Prognostic Value of Mean Platelet Volume-To-Monocyte Ratio and Ferritin in NSTEMI: Independent Impact of Angiotensin-Converting Enzyme Inhibitor Therapy · 2026 · Related
  13. Bipolar disorder · Iría Grande · 2015 · 1693 citations · Cited by this paper
  14. ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome · 2026 · Related
  15. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia · George A. Keepers · 2020 · 920 citations · Cited by this paper
  16. Process Improvement Is Not Yet Long-Term Effectiveness: Interpreting a Pharmacist-Provider Iron Deficiency Clinic · 2026 · Related
  17. Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors · Christoph Ulrich Correll · 2022 · 691 citations · Cited by this paper
  18. Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care · 2026 · Related
  19. The Psychopathology and Treatment of Bipolar Disorder · David J. Miklowitz · 2005 · 182 citations · Cited by this paper
  20. Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders · Daniil Grinchii · 2020 · 123 citations · Cited by this paper
  21. Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia · Andrew J. Cutler · 2008 · 113 citations · Cited by this paper
  22. Efficacy of Iloperidone in the Treatment of Schizophrenia · Steven G. Potkin · 2008 · 89 citations · Cited by this paper
  23. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion · Leslie Citrome · 2010 · 47 citations · Cited by this paper
  24. A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study · Peter J. Weiden · 2016 · 29 citations · Cited by this paper
  25. Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy · Fernanda S. Tonin · 2016 · 26 citations · Cited by this paper
  26. Neurostructural changes in schizophrenia and treatment-resistance: a narrative review · Tanya Paul · 2024 · 23 citations · Cited by this paper
  27. Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis · Qi Pei · 2016 · 17 citations · Cited by this paper
  28. Depot/Long Acting Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder · Halise Devrımcı Özgüven · 2021 · 13 citations · Cited by this paper
  29. Efficacy and Safety of Iloperidone in Bipolar Mania · Rosarelis Torres · 2024 · 11 citations · Cited by this paper
  30. BYSANTI (milsaperidone) · Paul R. Beninger · 2026 · 1 citation · Cited by this paper
  31. A review of functionality assessment scales in schizophrenia · Petru-Iulian Ifteni · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)